Trudell Medical Limited has invested in Adherium (Australia) as part of the company’s strategic plan to support organizations with innovative technologies that improve patient outcomes. Adherium is a provider of digital health solutions and a global leader in connected respiratory medical devices, with more than 170,000 sold globally. The company develops, manufactures and supplies a broad range of connected medical devices for respiratory medications for patients, pharmaceutical companies, healthcare providers and contract research organizations. Trudell subscribed $1,126,000 million of secured debt notes. The funds raised from the issue will be used for working capital purposes.